All News

Using Recentin (cediranib) can help stabilize disease in patients with alveolar soft-part sarcoma, a rare sarcoma subset.

A global trial recently launched that will investigate a personalized mRNA vaccine with Keytruda for patients with skin cancer.

If it wasn’t for my friends and family, I don’t know how I would have gotten through cancer alone.

Christina McAmis’ cancer journey began when she found a lump while breastfeeding. The attorney and mother of three tells the “Cancer Horizons” podcast what the last nine years have been like for her and her family.

Patients with a history of proton pump inhibitor use and who have NSCLC with a PD-L1 tumor proportion score of 50% or more benefit from immune checkpoint inhibitor plus chemotherapy as treatment.

When Black individuals learned about prostate cancer from Black doctors, they were more likely to trust the information, recent research showed.

We recently asked our audience of patients, survivors and caregivers about the ongoing cisplatin and carboplatin shortage. Here’s what they had to say.

It’s strange how an event can unfold on the national stage, and it validates something that you have been pointing out for years.

Recent developments in the use of immunotherapy for lung cancer have provided more treatment options for patients while potentially reducing side effect profiles.

It’s amazing the cancer resources and community we have now — something my mom didn’t have.

Larger liver resections do not always improve survival in patients with gallbladder cancer, recent research showed.

The Food and Drug Administration is reportedly expediting the review of Ambrx’s treatment for patients with metastatic, castration-resistant prostate cancer that has displayed promising early trial results.

New cancer treatments have offered me hope.

Caregivers of patients with head and neck cancer tend to face severe stress and burden related to their jobs, and it’s essential to implement more work-life balance.

Receiving a diagnosis of breast cancer and radiation treatment were both associated with increased rates of biological aging among patients who participated in a recent study.

Chemotherapy treatment can lead to bacterial changes in the gut and unhealthy weight gain for patients, with potential higher risk of morbidity and reduced quality of life, according to recent research.

Advancements have been made over the last decade in the use of immunotherapy for the treatment of skin cancers including melanoma, squamous cell carcinoma and Merkel cell carcinoma.

Sometimes difficult experiences like cancer can come with blessings in disguise.

Multiple considerations must be made when determining cancer treatment regimens amid the ongoing chemotherapy shortage, explained an oncologist.

Promacta tended to boost platelet counts in patients with low-risk MDS, and helped those patients be independent of transfusions, too.

Patients with a subset of acute myeloid leukemia may have improved survival rates and lower risk of relapse with Nexavar maintenance.

I am so happy that I was able to celebrate my wedding anniversary with my biggest supporter.

Adding Keytruda to chemoradiotherapy significantly improved progression-free survival for patients with newly diagnosed high-risk locally advanced cervical cancer.

Even with the increase of immunotherapy utilization to treat patients with advanced renal cell carcinoma, more research is needed to determine in which order to administer it as later lines of therapy.

The bonds that you make with your doctors can last a lifetime, and I’m so glad to call many of them a friend.

As Jill Biden helps to heighten Medicare for cancer patients, 15-year old swimmer raises money for Swim Across America and Carlos Carrasco furthers his program, “Cookie’s Kids,” this is what is happening in the oncology space this week.

The Food and Drug Administration approved a Vanflyta regimen for patients with FLT-ITD—positive acute myeloid leukemia.

Frontline Zejula maintenance therapy decreased the risk of disease progression or death in patients with newly diagnosed ovarian cancer.

Cost burdens are prevalent among patients with metastatic prostate cancer; however, utilizing appropriate resources could reduce costs up to 100%.

The treatment combination of Rybrevant and chemotherapy significantly improved progression-free survival rates for patients newly diagnosed with metastatic NSCLC with EGFR Exon 20 insertion mutations.